Form 4: RA Capital Management Reports Acquisition of Stock Options in Cidara Therapeutics

RA Capital Management and related parties report the acquisition of stock options in Cidara Therapeutics, Inc. on April 26, 2024.

Summary

• RA Capital Management, L.P., along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Cidara Therapeutics, Inc. securities.
• The report indicates the acquisition of stock options (right to buy) with an exercise price of $12.63 on April 26, 2024.
• A total of 4,250 stock options were acquired.
• These options vest over a period of two years, with one-third vesting on April 26, 2025, and the remaining two-thirds vesting in equal monthly installments until April 26, 2027.
• The expiration date for these options is April 25, 2034.
• The filing includes disclaimers of beneficial ownership by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, except to the extent of their pecuniary interest.
• Laura Tadvalkar, a Managing Director of the Adviser, holds the option for the benefit of the Fund and is obligated to turn over any net cash or stock received upon exercise of the option to offset advisory fees.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard filing indicating changes in ownership, with no explicit positive or negative implications.

Positives

• The acquisition of stock options by RA Capital Management could be interpreted as a sign of confidence in Cidara Therapeutics' future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.

Stakeholder Impact

• The acquisition of stock options by RA Capital Management may signal confidence to shareholders.

Key Dates